Literature DB >> 33170330

Airborne spread of SARS-CoV-2 while using high-flow nasal cannula oxygen therapy: myth or reality?

Andrew Haymet1,2, Gianluigi Li Bassi3,4,5, John F Fraser1,2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33170330      PMCID: PMC7652914          DOI: 10.1007/s00134-020-06314-w

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


× No keyword cloud information.
In 2020, a new pandemic caused by SARS-CoV-2 was declared [1], and since the first cases of coronavirus disease 2019 (COVID-19), clinicians had to apply different modes of respiratory support, previously used on patients with severe respiratory failure from other etiologies. In particular, high-flow nasal cannulae (HFNC) and non-invasive ventilation (NIV) were variably applied in early reports from China [2] and Europe [3]. Yet, the extent of airborne contamination of clinical areas during the use of HFNC has sparked intense debate and highlighted the need for inclusive investigation in this area. SARS-CoV-2 may be spread by direct or indirect contact with infected individuals through respiratory secretions or droplet transmission, as well as through fomites [4]. Once airborne, the half-life of SARS-CoV-2 is approximately one hour [95% credible interval, 0.64 to 2.64] [5]. Airborne transmission was initially underestimated; indeed in one analysis in February 2020 of 75,465 cases in China, airborne transmission was not reported [6]. A later study by Liu et al. from Wuhan analyzed aerosol samples using droplet digital polymerase chain reaction, and concluded that virus aerosol deposition on protective apparel or floor surface and their subsequent re-suspension was a conceivable transmission pathway [7]. These findings were further corroborated by Santarpia et al. on 13 isolated patients, who concluded that transmission may occur via contaminated objects and airborne transmission, as well as direct transmission via droplets [8]. Several other factors modulate the specific risk of healthcare workers (HCW) of being infected with SARS-CoV-2 and could be grouped into patient-related and HCW-related risk factors. Patient-related risks are associated with the volume and distance of respiratory particles generated and mobilized from the patient, the viral titre and long-term viability within the aerosolized particles, and finally the ability of the virus to penetrate innate host defenses. In contrast, HCW-related factors are associated to the HCW’s health status, comorbidities and immunocompetency, the length of time of exposure and adequacy of worn personal protective equipment (PPE). Patients with COVID-19 often present to the emergency department with substantial respiratory drive and persistent dry cough. Thus, based on the aforementioned evidence, viral transmission from respiratory particles and droplet dispersion may theoretically pose a significant risk to HCW, specifically in patients who are undergoing means of ventilatory support without shielding their mouths, and during the early days of hospital admission, when the viral load is the highest [9]. Unfortunately, to date, the literature describing risks of airborne contamination by HFNC versus other means of support, i.e. NIV via face mask or helmet or nose mask, is heavily reliant on preclinical data, not specifically focused on SARS-CoV-2, and thus is inducing rather than answering controversy in the field (Table 1). In an important preclinical study by Gaeckle and collaborators [10], particle concentration and size from the respiratory tract of 10 healthy individuals receiving oxygen with various modes of delivery were measured through an aerodynamic particle spectrometer. Importantly, no increase in the concentration of aerosols generated was found with the use of HFNC or NIV when compared with breathing room air or non-humidified oxygen modalities. However, it should be noted that this was a small study in healthy participants, without ongoing pulmonary disease, which limits extrapolations to patients infected by SARS-CoV-2. Indeed, these results were also contingent upon the method of sampling aerosolized particles, which in itself carries risk of sampling error. Furthermore, consistent results suggest that fitting of HFNC or NIV interfaces, i.e. nasal pillow/mask or face mask, plays a crucial role in droplet generation. In a study by Hui et al.[11], conducted on a human patient simulator of dispersion of traceable particles, the authors concluded that exhaled air dispersion was higher using NIV and dependent on the applied settings, as corroborated by substantial increases in dispersed air when NIV pressure was increased from 5 to 20 cmH2O or HFNC flow from 10 to 60 L/min. However, the highest dispersion was found by loosening the HF nasal cannulas or the HF oxygen circuit tube [11]. Tran et al.[12] studied the transmission of SARS from patients undergoing ventilatory support to HCW. They found that the virus could be dispersed through NIV, but not from HFNC or BiPAP mask adjustment. The study was limited by the small population and questionable methodology, and further emphasized the current lack of systematic appraisal of airborne viral transmission from infected patients. Finally, an in silico computational fluid dynamics simulation by Leonard et al. showed that using a simple surgical mask over the HFNC interface is effective in reducing distribution of aerosolized particles [13].
Table 1

Studies of risk of airborne contamination from HFNC versus other forms of ventilatory support, in settings both directly and not directly related to SARS-CoV-2

ReferenceVentilation techniques investigatedStudy design and sizeRelevant results
Studies directly related to SARS-COV-2
Guy T et al. (2020) High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU. Eur Respir J: 2,001,154HFNCClinical study (N = 27). Patients with RT-PCR-confirmed COVID-19 infection placed on HFNC for non-hypercapnic acute hypoxemic respiratory failureAfter a 30-day follow-up, only one nurse was infected with SARS-CoV-2 during the study period, potentially by domestic contact
Ahn JY et al. (2020) Environmental contamination in the isolation rooms of COVID-19 patients with severe pneumonia requiring mechanical ventilation or high-flow oxygen therapy. J Hosp Infect. S0195-6701(20)30,401–1HFNC, NIVClinical case series (N = 3). 3 patients with COVID-19 pneumonia (two mechanically ventilated, and one on HFNC/NIV)13 of the 28 environmental samples in a room of a patient receiving HFNC/NIV showed positive results and viable virus. Air samples were negative for SARS-CoV-2
Studies not directly related to SARS-COV-2, testing various types of ventilatory support and interfaces: corroboration of risk
Leonard S et al. (2020) Reducing aerosol dispersion by high-flow therapy in COVID-19: High resolution computational fluid dynamics simulations of particle behavior during high velocity nasal insufflation with a simple surgical mask. J Am Coll Emerg Physicians Open. 1(4):578–591HVNI, LFO2, and tidal breathingIn silico computational fluid dynamics simulation evaluating particle and droplet behavior with use of Type 1 surgical masksExhaled particulate mass capture by the mask was 88.8% (HVNI at 40L/min) vs 77.4% (LFO2 at 6 L/min). Particle distribution escaping to the room, (> 1 m from face) was 8.23% for HVNI + mask versus 17.2% for LFO2 + mask
 Leung CCH et al. (2019) Comparison of high-flow nasal cannula versus oxygen face mask for environmental bacterial contamination in critically ill pneumonia patients: a randomized controlled crossover trial. J Hosp Infect 101(1):84–87HFNC at 60L/min, and OM at 8.6 ± 2.2 L/minRandomized controlled crossover trial (N = 20). Environmental contamination by viable bacteria in critically ill patients with Gram-negative pneumonia receiving HFNC or OMThere were marginal differences in bacterial contamination between the HFNC and OM used
 Hui DS, (2015) Exhaled air dispersion during non-invasive ventilation via helmets and a total facemask. Chest. 147: 1336–1343NIV via two different helmets via a ventilator and total facemask via a bilevel positive airway pressure devicePreclinical study using human patient simulatorDuring NIV via a helmet with the lung simulator programmed in mild lung injury, exhaled air leaked through the neck-helmet interface with a radial distance of 150 to 230 mm when inspiratory positive airway pressure was increased from 12 to 20 cmH20. During NIV via a helmet with air cushion around the neck, there was negligible air leakage. During NIV via a total facemask for mild lung injury, air leaked through the exhalation port to 618 and 812 mm when inspiratory pressure was increased from 10 to 18 cmH2O, respectively, with the expiratory pressure at 5 cm H2O.
 Tran K, (2012) Aerosol Generating Procedures and Risk of Transmission of Acute Respiratory Infections to Healthcare Workers: A Systematic Review. PloS one. 7: e35797HFNC, NIV, BiPAPSystematic review; Ten non-randomized studies included (Five relevant case–control studies and five retrospective cohort studies)NIV was reported to present an increased risk of transmission of SARS to HCWs [n = 2 cohort; OR 3.1(1.4, 6.8)]. HFNC and manipulation of oxygen or BiPAP masks were not found to be significant in terms of risk to HCWs
Studies not directly related to COVID-19, testing various types of ventilatory support and interfaces: corroboration of safety
Gaeckle NT, (2020) Aerosol Generation from the Respiratory Tract with Various Modes of Oxygen Delivery. Am J Respir Crit Care Med. 202: 1115–1124Non-humidified NC, face mask, heated and humidified HFNC, and NIPPV, in a negative pressure roomClinical study (N = 10). Aerosol generation was measured from healthy participants with each oxygen mode during maneuvers of normal breathing, talking, deep breathing, and coughingOxygen delivery modalities of humidified HFNC and NIPPV did not increase aerosol generation from the respiratory tract
Studies not directly related to SARS-COV-2, with equivocal findings regarding risks
Agarwal A, (2020) High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission Can J Anaesth. 67(9):1217–1248HFNCSystematic review; seven studies included (six simulation studies, one crossover study)Included studies did not provide data that can be extrapolated to the risk of airborne transmission of SARS-CoV-2

HFNC high-flow nasal cannulae, NIV non-invasive ventilation, HVNI high velocity nasal insufflation, LFO low flow oxygen therapy, OM conventional oxygen mask, BiPAP bi-level positive airway pressure, NC  nasal cannula, NIPPV non-invasive positive pressure ventilation, NRB non-rebreather mask

Studies of risk of airborne contamination from HFNC versus other forms of ventilatory support, in settings both directly and not directly related to SARS-CoV-2 HFNC high-flow nasal cannulae, NIV non-invasive ventilation, HVNI high velocity nasal insufflation, LFO low flow oxygen therapy, OM conventional oxygen mask, BiPAP bi-level positive airway pressure, NC  nasal cannula, NIPPV non-invasive positive pressure ventilation, NRB non-rebreather mask In the setting of SARS-CoV-2, evidence on this subject is highly limited and anecdotal. Various investigators have suggested that HFNC and NIV are associated with proven aerosolization of viable virus particles around the patient bedspace, but failed to establish a clear association with an increased number of HCW infections. To illustrate, one clinical study demonstrated that distribution of viable virus particles throughout the immediate clinical environment occurred with HFNC and NIV [14]. A separate clinical study showed that when staff were fully trained in the use of PPE, the rate of HCW infection whilst being in the immediate vicinity of HFNC was extremely low [15]. More high-quality evidence is clearly needed to better establish the true risk of infection to HCWs from aerosolization. For HFNC, the continued perception of a risk of viral aerosolization remains a significant obstacle to its uptake for management of hypoxemic respiratory failure in COVID-19, as highlighted by discordant recommendations on its use from health organizations and medical societies across the globe. Nevertheless, potential risks should be balanced with the described benefits with the use of HFNC, even in COVID-19 patients in the prone position. Taken together, airborne contamination via generation of aerosols during HFNC must at this stage be assumed as conceivable and potentially perilous to the HCW, until proven otherwise. Preclinical data, whilst useful to establish the mechanics of aerosolization, unfortunately do not capture the endpoint of absolute risk, which ultimately depends on the quantity and viability of pathogenic material and specific HCW risks. In the meanwhile, reducing dispersion through simple measures, such as surgical masks and careful fitting of the interfaces and sealing of the circuit on supported patients are strongly recommended. Further clinical research, and particularly systematic human studies, which can correlate the degree of ventilation-dispersed aerosols with the quantity and viability of dispersed virulent particles that are capable of causing infection, are urgently required.
  11 in total

1.  Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals.

Authors:  Yuan Liu; Zhi Ning; Yu Chen; Ming Guo; Yingle Liu; Nirmal Kumar Gali; Li Sun; Yusen Duan; Jing Cai; Dane Westerdahl; Xinjin Liu; Ke Xu; Kin-Fai Ho; Haidong Kan; Qingyan Fu; Ke Lan
Journal:  Nature       Date:  2020-04-27       Impact factor: 49.962

2.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.

Authors:  Giacomo Grasselli; Alberto Zangrillo; Alberto Zanella; Massimo Antonelli; Luca Cabrini; Antonio Castelli; Danilo Cereda; Antonio Coluccello; Giuseppe Foti; Roberto Fumagalli; Giorgio Iotti; Nicola Latronico; Luca Lorini; Stefano Merler; Giuseppe Natalini; Alessandra Piatti; Marco Vito Ranieri; Anna Mara Scandroglio; Enrico Storti; Maurizio Cecconi; Antonio Pesenti
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

3.  Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks.

Authors:  David S Hui; Benny K Chow; Thomas Lo; Owen T Y Tsang; Fanny W Ko; Susanna S Ng; Tony Gin; Matthew T V Chan
Journal:  Eur Respir J       Date:  2019-04-11       Impact factor: 16.671

Review 4.  Monitoring approaches for health-care workers during the COVID-19 pandemic.

Authors:  Julia A Bielicki; Xavier Duval; Nina Gobat; Herman Goossens; Marion Koopmans; Evelina Tacconelli; Sylvie van der Werf
Journal:  Lancet Infect Dis       Date:  2020-07-23       Impact factor: 25.071

5.  Environmental contamination in the isolation rooms of COVID-19 patients with severe pneumonia requiring mechanical ventilation or high-flow oxygen therapy.

Authors:  J Y Ahn; S An; Y Sohn; Y Cho; J H Hyun; Y J Baek; M H Kim; S J Jeong; J H Kim; N S Ku; J-S Yeom; D M Smith; H Lee; D Yong; Y-J Lee; J W Kim; H R Kim; J Hwang; J Y Choi
Journal:  J Hosp Infect       Date:  2020-08-21       Impact factor: 3.926

6.  Aerosol Generation from the Respiratory Tract with Various Modes of Oxygen Delivery.

Authors:  Nathaniel T Gaeckle; Jihyeon Lee; Yensil Park; Gean Kreykes; Michael D Evans; Christopher J Hogan
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

Review 7.  Aerosol generating procedures and risk of transmission of acute respiratory infections to healthcare workers: a systematic review.

Authors:  Khai Tran; Karen Cimon; Melissa Severn; Carmem L Pessoa-Silva; John Conly
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

8.  Reducing aerosol dispersion by high flow therapy in COVID-19: High resolution computational fluid dynamics simulations of particle behavior during high velocity nasal insufflation with a simple surgical mask.

Authors:  Scott Leonard; Wayne Strasser; Jessica S Whittle; Leonithas I Volakis; Ronald J DeBellis; Reid Prichard; Charles W Atwood; George C Dungan
Journal:  J Am Coll Emerg Physicians Open       Date:  2020-06-11

9.  High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU.

Authors:  Tiphaine Guy; Audrey Créac'hcadec; Charles Ricordel; Alexandre Salé; Baptiste Arnouat; Jean-Louis Bizec; Marie Langelot; Christine Lineau; David Marquette; Françoise Martin; Mathieu Lederlin; Stéphane Jouneau
Journal:  Eur Respir J       Date:  2020-11-12       Impact factor: 16.671

10.  Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.

Authors:  Neeltje van Doremalen; Trenton Bushmaker; Dylan H Morris; Myndi G Holbrook; Amandine Gamble; Brandi N Williamson; Azaibi Tamin; Jennifer L Harcourt; Natalie J Thornburg; Susan I Gerber; James O Lloyd-Smith; Emmie de Wit; Vincent J Munster
Journal:  N Engl J Med       Date:  2020-03-17       Impact factor: 91.245

View more
  12 in total

1.  The effectiveness of high-flow nasal cannula and standard non-rebreathing mask for oxygen therapy in moderate category COVID-19 pneumonia: Randomised controlled trial.

Authors:  N Nazir; A Saxena
Journal:  Afr J Thorac Crit Care Med       Date:  2022-05-05

Review 2.  High-Flow Nasal Oxygen and Noninvasive Ventilation for COVID-19.

Authors:  Hasan M Al-Dorzi; John Kress; Yaseen M Arabi
Journal:  Crit Care Clin       Date:  2022-01-10       Impact factor: 3.879

3.  High-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure.

Authors:  Ricard Mellado-Artigas; Bruno L Ferreyro; Federico Angriman; María Hernández-Sanz; Egoitz Arruti; Antoni Torres; Jesús Villar; Laurent Brochard; Carlos Ferrando
Journal:  Crit Care       Date:  2021-02-11       Impact factor: 9.097

Review 4.  Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic.

Authors:  Kelvin Kai-Wang To; Siddharth Sridhar; Kelvin Hei-Yeung Chiu; Derek Ling-Lung Hung; Xin Li; Ivan Fan-Ngai Hung; Anthony Raymond Tam; Tom Wai-Hin Chung; Jasper Fuk-Woo Chan; Anna Jian-Xia Zhang; Vincent Chi-Chung Cheng; Kwok-Yung Yuen
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

5.  Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method.

Authors:  Prashant Nasa; Elie Azoulay; Ashish K Khanna; Ravi Jain; Sachin Gupta; Yash Javeri; Deven Juneja; Pradeep Rangappa; Krishnaswamy Sundararajan; Waleed Alhazzani; Massimo Antonelli; Yaseen M Arabi; Jan Bakker; Laurent J Brochard; Adam M Deane; Bin Du; Sharon Einav; Andrés Esteban; Ognjen Gajic; Samuel M Galvagno; Claude Guérin; Samir Jaber; Gopi C Khilnani; Younsuck Koh; Jean-Baptiste Lascarrou; Flavia R Machado; Manu L N G Malbrain; Jordi Mancebo; Michael T McCurdy; Brendan A McGrath; Sangeeta Mehta; Armand Mekontso-Dessap; Mervyn Mer; Michael Nurok; Pauline K Park; Paolo Pelosi; John V Peter; Jason Phua; David V Pilcher; Lise Piquilloud; Peter Schellongowski; Marcus J Schultz; Manu Shankar-Hari; Suveer Singh; Massimiliano Sorbello; Ravindranath Tiruvoipati; Andrew A Udy; Tobias Welte; Sheila N Myatra
Journal:  Crit Care       Date:  2021-03-16       Impact factor: 9.097

6.  [Low incidence of SARS-CoV-2 infections in healthcare workers at a tertiary care hospital : Results of a prospective serological cohort study of the first and second COVID‑19 pandemic wave].

Authors:  Julian Hupf; Ralph Burkhardt; André Gessner; Constantin Maier-Stocker; Markus Zimmermann; Frank Hanses; David Peterhoff
Journal:  Med Klin Intensivmed Notfmed       Date:  2022-01-03       Impact factor: 1.552

7.  First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy.

Authors:  Marianna Meschiari; Alessandro Cozzi-Lepri; Roberto Tonelli; Erica Bacca; Marianna Menozzi; Erica Franceschini; Gianluca Cuomo; Andrea Bedini; Sara Volpi; Jovana Milic; Lucio Brugioni; Elisa Romagnoli; Antonello Pietrangelo; Elena Corradini; Irene Coloretti; Emanuela Biagioni; Stefano Busani; Massimo Girardis; Andrea Cossarizza; Enrico Clini; Giovanni Guaraldi; Cristina Mussini
Journal:  BMJ Open       Date:  2022-01-03       Impact factor: 2.692

8.  Quantification of aerosol dispersal from suspected aerosol-generating procedures.

Authors:  Runar Strand-Amundsen; Christian Tronstad; Ole Elvebakk; Tormod Martinsen; Marius Dybwad; Egil Lingaas; Tor Inge Tønnessen
Journal:  ERJ Open Res       Date:  2021-12-06

9.  Outcome Improvement Between the First Two Waves of the Coronavirus Disease 2019 Pandemic in a Single Tertiary-Care Hospital in Belgium.

Authors:  Bernard Lambermont; Anne-Françoise Rousseau; Laurence Seidel; Marie Thys; Jonathan Cavalleri; Pierre Delanaye; J Geoffrey Chase; Pierre Gillet; Benoit Misset
Journal:  Crit Care Explor       Date:  2021-05-19

Review 10.  Respiratory care for the critical patients with 2019 novel coronavirus.

Authors:  Yao-Chen Wang; Min-Chi Lu; Shun-Fa Yang; Mauo-Ying Bien; Yi-Fang Chen; Yia-Ting Li
Journal:  Respir Med       Date:  2021-06-21       Impact factor: 3.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.